$0.01
(Market cap
$62 Mln
Revenue (TTM)
$151 Mln
P/E Ratio
--
P/B Ratio
10.9
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$0 Mln
-
ROE
-24.1 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
35
-
Debt to Equity
0
-
Book Value
$--
-
EPS
$-0.2
-
Face value
--
-
Shares outstanding
189,852,307
10 Years Aggregate
CFO
$-1,353.47 Mln
EBITDA
$-1,642.69 Mln
Net Profit
$-1,615.34 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Heron Therapeuti (HRTX)
| -73.8 | -33.5 | -23.9 | -74.4 | -39.9 | -50.7 | -32.6 |
|
BSE Sensex
| -9.6 | -2.7 | 2.9 | -5.0 | 5.4 | 5.7 | 10.4 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Heron Therapeuti (HRTX)
| -15.0 | -9.9 | -32.0 | -72.6 | -56.9 | -9.9 | -9.4 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Heron Therapeuti (HRTX)
|
0.3 | 62.0 | 151.2 | -34.1 | -16.3 | -320.6 | -- | 10.9 |
| 84.8 | 11,993.9 | 669.5 | -320.0 | -0.8 | -71.1 | -- | 26.9 | |
| 268.4 | 16,261.1 | 1,054.4 | 755.9 | 5.7 | -- | 19 | 9.8 | |
| 72.4 | 10,022.2 | 71.0 | -894.0 | -1,175.8 | -- | -- | 60.3 | |
| 59.0 | 13,491.7 | 2,435.9 | 860.6 | 31.0 | 43 | 17.4 | 7.4 | |
| 110.2 | 11,957.0 | 1,663.7 | 413.6 | 36.3 | 430 | 30.9 | 84.5 | |
| 355.5 | 10,402.8 | 440.5 | 241.5 | 33.4 | 18.7 | 44.1 | 7.8 | |
| 118.2 | 9,718.7 | 105.0 | -299.7 | -227.2 | -19.4 | -- | 6.6 | |
| 541.4 | 12,332.1 | 1,283.9 | -325.1 | -19.0 | -57.7 | -- | 24.0 | |
| 592.0 | 16,765.1 | 2,782.3 | 491.5 | 21.1 | 110.1 | 35.2 | 39.3 |
Shareholding Pattern
View DetailsAbout Heron Therapeuti (HRTX)
Heron Therapeutics, Inc., a commercial-stage biotechnology company, engages in developing and commercializing therapeutic that enhances medical care. The company's product candidates utilize its proprietary Biochronomer, a drug delivery technology,... which delivers therapeutic levels of a range of short-acting pharmacological agents over a period from days to weeks with a single administration. It offers SUSTOL (granisetron), an extended-release injection for the prevention of acute and delayed nausea and vomiting associated with moderately emetogenic chemotherapy, or anthracycline and cyclophosphamide combination chemotherapy regimens; and CINVANTI, an intravenous formulation of aprepitant, a substance P/neurokinin-1 receptor antagonist for the prevention of acute and delayed nausea and vomiting associated with highly emetogenic cancer chemotherapy, as well as nausea and vomiting associated with moderately emetogenic cancer chemotherapy. The company is also developing ZYNRELEF, a dual-acting local anesthetic that delivers a fixed-dose combination of the local anesthetic bupivacaine and a low dose of the nonsteroidal anti-inflammatory drug meloxicam; and APONVIE, an intravenous formulation of a substance P/neurokinin-1 receptor antagonist indicated for the prevention of postoperative nausea and vomiting in adults. Heron Therapeutics, Inc. was formerly known as A.P. Pharma, Inc. and changed its name to Heron Therapeutics, Inc. in January 2014. The company was founded in 1983 and is headquartered in Cary, North Carolina. Read more
-
CEO & Director
Mr. Craig Alexander Collard
-
CEO & Director
Mr. Craig Alexander Collard
-
Headquarters
Cary, NC
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Heron Therapeuti (HRTX)
What is the current share price of Heron Therapeuti (HRTX) Today?
The share price of Heron Therapeuti (HRTX) is $0.34 (NASDAQ) as of 04-Sep-2026 13:38 EDT. Heron Therapeuti (HRTX) has given a return of -39.94% in the last 3 years.
What is the current PB & PE ratio of Heron Therapeuti (HRTX)?
Since, TTM earnings of Heron Therapeuti (HRTX) is negative, P/E ratio is not available.
The P/B ratio of Heron Therapeuti (HRTX) is 10.94 times as on 28-Aug-2026, a 111 premium to its peers’ median range of 5.18 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
2025 |
-10.73 |
15.12 |
2024 |
-17.25 |
-6.96 |
2023 |
-2.31 |
-7.52 |
2022 |
-2.21 |
21.95 |
2021 |
-4.28 |
12.00 |
What is the 52 Week High and Low of Heron Therapeuti (HRTX)?
The 52-week high and low of Heron Therapeuti (HRTX) are Rs 1.58 and Rs 0.30 as of 05-Sep-2026.
What is the market cap of Heron Therapeuti (HRTX)?
Heron Therapeuti (HRTX) has a market capitalisation of $ 62 Mln as on 28-Aug-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Heron Therapeuti (HRTX)?
Before investing in Heron Therapeuti (HRTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.